BCG Therapy for Type 1 Diabetes: Restoration of Balanced Immunity and Metabolism.
BCG vaccine
TNF
Tregs
aerobic glycolysis
oxidative phosphorylation
type 1 diabetes
Journal
Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
09
09
2018
revised:
10
11
2018
accepted:
27
11
2018
pubmed:
3
1
2019
medline:
31
12
2019
entrez:
3
1
2019
Statut:
ppublish
Résumé
The bacillus Calmette-Guerin (BCG) vaccine is a microorganism developed as a vaccine for tuberculosis 100 years ago and used as therapy for bladder cancer 40 years ago. More recently, BCG has shown therapeutic promise for type 1 diabetes (T1D) and several other autoimmune diseases. In T1D, BCG restored blood sugars to near normal, even in patients with advanced disease of >20 years duration. This clinically important effect may be driven by resetting of the immune system and the shifting of glucose metabolism from overactive oxidative phosphorylation, a state of minimal sugar utilization, to aerobic glycolysis, a state of high glucose utilization, for energy production. The mechanistic findings support the Hygiene Hypothesis and reveal the immune and metabolic synergy of mycobacterial reintroduction in modern humans.
Identifiants
pubmed: 30600132
pii: S1043-2760(18)30212-1
doi: 10.1016/j.tem.2018.11.006
pii:
doi:
Substances chimiques
BCG Vaccine
0
Blood Glucose
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
80-92Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.